Vicore Pharma Holding (OM:VICO BTA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VICO BTA Stock Overview

A clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases.

About the company

VICO BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 26.5% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Vicore Pharma Holding AB (publ) Competitors

Mendus

OM:IMMU

SEK 412.4m

Hansa Biopharma

OM:HNSA

SEK 2.7b

Alligator Bioscience

OM:ATORX

SEK 956.6m

Cereno Scientific

OM:CRNO B

SEK 1.5b

Price History & Performance

Summary of all time highs, changes and price drops for Vicore Pharma Holding
Historical stock prices
Current Share Price	SEK 8.86
52 Week High	SEK 8.96
52 Week Low	SEK 7.30
Beta	0.68
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	15.06%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VICO BTA	SE Biotechs	SE Market
7D	9.7%	3.5%	-0.1%
1Y	n/a	37.0%	28.5%

Return vs Industry: Insufficient data to determine how VICO BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how VICO BTA performed against the Swedish Market.

Price Volatility

Is VICO BTA's price volatile compared to industry and market?
VICO BTA volatility
VICO BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.3%
10% most volatile stocks in SE Market	11.5%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: VICO BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine VICO BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	28	Ahmed Mousa	www.vicorepharma.com

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB (publ) Fundamentals Summary

How do Vicore Pharma Holding's earnings and revenue compare to its market cap?
VICO BTA fundamental statistics
Market cap	SEK 2.09b
Earnings (TTM)	-SEK 200.06m
Revenue (TTM)	SEK 104.24m

20.1x

P/S Ratio

-10.5x

P/E Ratio

Is VICO BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VICO BTA income statement (TTM)
Revenue	SEK 104.24m
Cost of Revenue	SEK 0
Gross Profit	SEK 104.24m
Other Expenses	SEK 304.31m
Earnings	-SEK 200.06m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 05, 2024

Earnings per share (EPS)	-0.85
Gross Margin	100.00%
Net Profit Margin	-191.92%
Debt/Equity Ratio	0%

How did VICO BTA perform over the long term?

See historical performance and comparison